It seems that the Pfizer vaccine is not as effect in people of Asian descent, while it maybe true the Sinovac maybe more effective in Asian people then in non-Asian people. Consider the populations the vaccine was developed in, this could have contributed to the dichotomy.
We need to study the populations (sample of the genetic break down of those where it was not effective) getting the vaccines after the fact; Meta-analysis, to find out the true efficacy.
either way, if you have the opportunity to get any of the vaccines with credible phase 3 data, it would still be best to get any of those vaccines then to go unvaccinated.
That is true, and Indonesian share more similarity with Chinese Han in DNA
Yup, it is the emergency situation and Indonesia has also bought other vaccines greatly, we have bought 50 million Covid 19 vaccine as well from Pfizer. Indonesia bought 100 million raw material vaccine from Sinovac, but in total we have secured about 350 million dose of vaccine. It is enough for this year until our own made vaccine is ready inshaAllah. Our own made vaccine uses Indonesian Covid 19 strain and uses more modern method than Sinovac from China.
-------------------------------------------------------------------------------------
LIPI, UI join Merah Putih vaccine development team
News Desk
The Jakarta Post Jakarta / Fri, December 4, 2020 / 06:24 pm
The Indonesian Institute of Sciences (LIPI) and the University of Indonesia (UI) have joined the national team for the development of a COVID-19 vaccine. The two organizations are now allowed to research COVID-19 candidate vaccines to help the country develop and produce one in the future – to be called the Merah Putih vaccine.
Research and Technology Minister and National Research and Innovation Agency (BRIN) head Bambang Brodjonegoro said Indonesia would need many vaccine doses because of the size of its population. The country would also need doses for revaccination.
“Therefore, apart from having foreign partnerships for vaccine procurement, we also need to develop a vaccine locally in order to be self-reliant,” he said on Thursday, as quoted by kompas.id. “We hope that the involvement of the LIPI and UI can help meet vaccine needs in Indonesia.” Previously, the Eijkman Institute for Molecular Biology and Airlangga University received the ministry’s approval to assist in the development of the Merah Putih vaccine.
The government hoped to progress quickly through the development and testing phase. “[The candidate vaccine] is about 55 percent through the laboratory stage,” said Eijkman Institute for Molecular Biology head Amin Soebandrio in October, as quoted by tribunnews.com.
“It is hoped that preclinical animal testing can be carried out next month, and if everything runs smoothly we can finish development of the vaccine by the end of the year, and early next year the vaccine concentrate can be submitted to Bio Farma." The candidate vaccine is now set to undergo trials in February and March of next year.
The Bandung Institute of Technology (ITB) and Gadjah Mada University (UGM) are also involved in the country’s vaccine development efforts. All of the locally developed candidate vaccines use strains of the virus found and analyzed in Indonesia.
“In 2021, the budget will be around Rp 300 billion [US$21.24 million],” said Bambang.
www.thejakartapost.com